XXXX is superior to @entity2983 in the time to improvement of signs and symptoms of acute mild-to-moderate @entity31 .

@entity1 @entity548 @entity24740 @entity31 @entity38169 @entity2983
OBJECTIVE: @entity38169 is a novel @entity24740 -bonded @entity2983 treatment for mild-to-moderate @entity31 . The study objective was to compare symptomatic remission rates with @entity38169 and @entity2983 while controlling for extent of disease and time since diagnosis in @entity1 with active, mild-to-moderate @entity31 . METHODS: A total of 173 @entity1 with sigmoidoscopically verified @entity31 were randomized to 8 wk of double-blind treatment with @entity38169 6.75 g/day or @entity2983 2.4 g/day. Both treatments provided 2.4 g/day of oral @entity2983 . @entity1 maintained symptom diaries throughout the treatment period. RESULTS: Overall, 46% of @entity38169 - and 44% of @entity2983 -treated @entity1 achieved symptomatic remission. Higher response rates were noted in newly diagnosed @entity1 with < or = 40 cm of disease (68% vs 61%) than in recently relapsed @entity1 with >40 cm of disease (36% vs 25%). The median time to symptomatic remission was 12 days shorter with @entity38169 (25 days) than with @entity2983 (37 days). Significantly more @entity38169 @entity1 showed sigmoidoscopic (p = 0.002), stool frequency (p = 0.006), @entity548 (p = 0.006), and physician's global assessment score (p = 0.013) improvement by 14 days than did @entity2983 @entity1 . Similar proportions of @entity1 reported adverse events (54% vs 64%), which were most commonly related to the gastrointestinal and central and peripheral nervous systems. CONCLUSIONS: @entity38169 is an effective and safe treatment for mild-to-moderate @entity31 . Improvement of symptoms occurs considerably earlier with @entity38169 than with @entity2983 .
